Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Antitumor Activity of ARR-002 in Adults With Locally Advanced or Metastatic Ovarian or Endometrial Cancer.

NCT07755436 is registered in ClinicalTrials.gov with ArriVent BioPharma, Inc. as lead sponsor.

NCT NCT07755436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07755436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Antitumor Activity of ARR-002 in Adults With Locally Advanced or Metastatic Ovarian or Endometrial Cancer.
Lead sponsor
ArriVent BioPharma, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 23, 2026
Completion date
May 31, 2029
Enrollment
180 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, metastatic endometrial cancer, metastatic ovarian cancer, ovarian cancer, platinum-resistant ovarian cancer (proc)